AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
 Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
 with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
 in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
 Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
 is performed.
In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner.
 Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done
 with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone
 in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine.
 Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA
 is performed.
Inclusion Criteria:

 -  acute promyelocytic leukemia confirmed by detection of t(15;17) and/or PML/RARa

 -  no contraindication for chemotherapy

 -  written informed consent

 Exclusion Criteria:

 - severe comorbidities